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Tumor behavior is not entirely determined by tumor cells. Studies have demonstrated that a variety of non-tumor cells
in the tumor microenvironment affect tumor behavior; thus, a new focus of cancer research has been the development
of novel cancer treatment ideas and therapeutic targets based on the effects of these cells. Mesenchymal stem cells
(MSCs) are an important component of the tumor microenvironment; however, previous studies have produced
controversial results regarding whether MSCs promote or inhibit tumor growth and progression. In particular, Naïve
MSCs and tumor-derived MSCs (T-MSCs) have different functions. Naïve MSCs could exert bidirectional effects on
tumors because these cells can both promote and inhibit tumor progression while T-MSCs promote tumor progression
due to influences from the tumor itself and from the inflammatory tumor microenvironment. As an unhealed wound,
tumor produces a continuous source of inflammatory mediators and causes aggregation of numerous inflammatory
cells, which constitute an inflammatory microenvironment. Inflammatory factors can induce homing of circulating
MSCs and MSCs in adjacent tissues into tumors, which are then being “educated” by the tumor microenvironment to
support tumor growth. T-MSCs could recruit more immune cells into the tumor microenvironment, increase the
proportion of cancer stem cells and promote tumor angiogenesis, further supporting tumor progression. However,
as plasticity is a fundamental feature of MSCs, MSCs can also inhibit tumors by activating various MSC-based
signaling pathways. Studies of the mechanisms by which interactions among tumors, MSCs, and the inflammatory
microenvironment occur and methods to disrupt these interactions will likely reveal new targets for cancer therapy.
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In 2000, Hanahan and Weinberg summarized the hallmarks
of cancer, which included the following capabilities:
self-sufficiency with regard to growth signals, apoptosis
evasion, insensitivity to anti-growth signals, sustained
angiogenesis, tissue invasion & metastasis, and a limitless
replicative potential [1]. However, recent studies have
demonstrated that tumor behavior is not completely
determined by tumor cells alone; in particular, the
roles of cytokines and non-tumor cells in the tumor
microenvironment during tumorigenesis and tumor
development have drawn increased research attention [2].* Correspondence: chunhuaz@public.tpt.tj.cn
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stated.Tumors are now regarded as chronic injuries that are
difficult to heal [3], and inflammation is known to play an
important role in tumorigenesis, tumor progression, and
metastasis [4,5].
The main cytokines present in the inflammatory tumor
microenvironment include inflammatory cytokines such
as tumor necrosis factor α (TNF-α) [6], interferon-gamma
(IFN-γ) [7], interleukin-6 (IL-6) [8,9], IL-8 [8], IL-1, and
transforming growth factor-beta (TGF-β); growth factors
such as hepatocyte growth factor (HGF), platelet-derived
growth factor (PDGF), and vascular endothelial growth
factor (VEGF); chemokines such as stromal cell-derived
factor-1 (SDF-1) [10]; and other factors such as matrix
metalloproteinases. The main non-tumor cells present in
the inflammatory tumor microenvironment include
inflammatory cells such as lymphocytes, macrophages,
and myeloid-derived suppressor cells [11]; vascular
endothelial cells; and tumor-associated stromal cells such
as tumor-associated fibroblasts (TAFs) and MSCs [12].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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development.
MSCs were first discovered in the bone marrow,
although they account for only 1/105 nucleated bone
marrow cells. MSCs and MSC-differentiated stromal
cells play supportive roles in hematopoiesis and hold
potential for a variety of diseases [13]. Chromosomal or
functional abnormalities in MSCs could be present in
various malignant hematological diseases such as
myelodysplastic syndromes [14,15], lymphocytic leukemia
[16], multiple myeloma [17], acute myeloid leukemia [18,19],
and chronic myeloid leukemia [20]. Defects in MSCs
can lead to hematopoietic abnormalities. It has been
conjectured that MSCs might also exhibit functional
abnormalities in solid tumors. MSCs are not particularly
prevalent in solid tumor tissues, accounting for only 0.01%
of the total cell number within these tissues [21]. However,
the role of MSCs in this context has drawn increasing
attention from researchers.
Prior reports have produced controversial results
regarding the roles of MSCs in solid tumors. Certain
studies have demonstrated that MSCs can inhibit tumor
proliferation [22] and promote tumor cell apoptosis [23],
whereas other investigations have revealed that MSCs
promote the epithelial-mesenchymal transition (EMT)
during tumor progression [24] and increase the proportion
of stem cells in tumors [25]. MSC membranes express
receptors for a number of different growth factors
and inflammatory cytokines, and MSCs exhibit plasticity;
specifically, in different microenvironments or under
different induction conditions, MSCs can differentiate into
cells of various types or functions that play different
roles in tumor development. Therefore, studies of the
tumor-specific roles of MSCs must account for the effects
of the inflammatory tumor microenvironment.
Below, we will separately discuss the effects of tumors
and the tumor inflammatory microenvironment on MSC
homing and differentiation, the different functions of
naïve MSCs from normal tissues and tumor tissue-derived
MSCs (tumor tissue-educated MSCs; T-MSCs), and the
potential mechanisms by which tumors “educate” MSCs.
The mechanisms of MSC homing to tumor tissues
The influence of the inflammatory tumor microenvironment
enables MSCs to specifically home to tumor tissues while
avoiding peritumoral normal tissues [24]. MSCs can home to
nearly all inflammation sites, including ischemic myocardial
tissues, wounded skin regions, and the gastrointestinal
mucosa after radiotherapy.
Researchers have established a tumor model in which
MSCs isolated from fluorescent mice are introduced into
non-fluorescent mice (by either replacing the bone
marrow cells of the tumor-bearing mice with enhanced
green fluorescent protein (EGFP)-positive bone marrowcells or by subcutaneously transplanting EGFP-positive
adipose tissues into tumor-bearing mice) [26]. The results
from this model have demonstrated that MSCs in mouse
tumor tissues might be derived from the bone marrow; in
other words, these MSCs might be circulating bone
marrow MSCs. Adipose tissues near tumors provide
another source of MSCs in tumors. There are certain
differences in the outcomes produced in tumor tissues by
MSCs derived from these two sources.
Tumors and their microenvironments induce MSC
homing through mechanisms that depend mainly on
various inflammatory cytokines, chemokines, growth
factors, and other factors (Figure 1). These major factors
in MSC homing are discussed below. First, inflammatory
cytokines. The first step in the homing of circulating
MSCs to tumor tissue is MSCs adhesion to the vascular
endothelium, followed by crossing of the endothelial
layer. Uchibori et al. and Teo et al. detected high
concentrations of TNF-α in tumor tissues. TNF-α upregu-
lates vascular cell adhesion molecule-1 (VCAM-1) expres-
sion on MSCs, thereby promoting the adhesion of MSCs to
endothelial cells. IL-1β and IFN-γ can produce similar
effects [27,28]. Because MSCs express IL-6 receptors, high
IL-6 concentrations in tumor tissues could directly induce
the accumulation of MSCs in these tissues. Additionally,
Liu et al. found that IL-6 induces high expression levels of
the CXC motif ligand (CXCL) chemokines CXCL7, CXCL6,
and CXCL5 in MSCs [29]. Second, chemokines. Tumor
cells secrete large quantities of SDF-1 [30,31], and MSCs
express the SDF-1 receptor CXC chemokine receptor 4
(CXCR4). Therefore, an SDF-1 concentration gradient
could induce MSC migration [32]. Third, growth factors.
PDGF, HGF, and other growth factors could induce
the migration of MSCs to tumor cells [27,33]. Finally, other
factors. Various other factors such as hypoxia-inducible
factor 1 (HIF-1) also play crucial roles in MSC homing.
Tumors typically grow under hypoxic conditions. In
hypoxic environments, breast cancer cells express high
levels of HIF-1, which promotes the expression of CXC
chemokine receptor 3 (CXCR3) and CXC chemokine
receptor 5 (CXCR5) on breast cancer cell lines. MSCs
express high levels of CXCL10 and the chemokine CC
motif ligand 5 (CCL5). Therefore, MSCs are recruited
to breast cancer areas and can promote breast cancer
metastasis to the lung and lymph nodes. Thus, the homing
of MSCs to tumors results from the combined effects of
multiple cytokines. The major cytokines involved in this
process are summarized in Table 1 (below).The outcomes of MSC homing to tumor tissues
MSCs are known to exhibit plasticity. MSCs that home
to tumors can exist in 3 forms due to the effects of the
inflammatory tumor microenvironment.
Figure 1 Homing of MSCs to tumors. As a wound that doesn’t heal, tumor produces a continuous source of inflammatory mediators and
causes aggregation of numerous inflammatory cells, which constitute an inflammatory microenvironment. Inflammatory mediators could attract
MSCs from bone marrow or adjacent adipose tissues and these MSCs become a major component of tumor microenvironment.
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continue to exist as MSCs. Numerous studies have
confirmed that MSCs can be isolated from solid
tumor tissues. These isolated MSCs are similar to
normal tissue-derived MSCs (N-MSCs) with respect to
morphology, phenotype, and multilineage differentiation
capacity. However, T-MSCs and N-MSCs exhibit significant
functional differences. We will describe these differences
in detail later in this paper.
In tumor tissues, MSCs can also differentiate into
tumor-associated myofibroblasts (TAFs; also known as
cancer-associated myofibroblasts). TAFs and MSCs
exhibit similar phenotypes; additionally, both cell
types secrete similar cytokines. However, compared to
MSCs, TAFs secrete significantly higher levels of TGF-β,
VEGF, IL-4, and IL-10 [41,42]; moreover, TAFs express
various specific markers such as α-smooth muscle
actin (α-SMA), PDGF receptor-β (PDGFR-β), desmin,
fibroblast-specific protein (FSP), and fibroblast activation
protein (FAP) [26,43-46]. TAFs isolated from tumors or
tumor-conditioned medium-induced myofibroblasts
promote tumor growth, whereas myofibroblast-like cells
derived from 5-azacytidine-induced MSCs do not produce
this effect.
Tumor tissues contain large quantities of various
angiogenic factors such as VEGF. In vitro studies have
revealed that VEGF induction can induce MSCs to
differentiate into vascular endothelial cells and even
form three-dimensional vascular structures. However,
the question of whether MSCs within tumors candifferentiate into vascular endothelial cells in vivo remains
controversial. In mouse models of breast cancer [44] and
colon cancer [45], MSCs promoted tumor angiogenesis but
did not differentiate into cluster of differentiation 31
(CD31) or von Willebrand factor (vWF)-positive endothelial
cells. MSCs have only been known to differentiate into
CD31-positive vascular endothelial cells, rather than into
TAFs (α-SMA-positive cells), in a mouse model of
melanoma [47]. An in vivo study by Kidd et al. found
that the FAP+ and FSP+ TAF cells in tumor tissues were
mainly derived from bone marrow MSCs, whereas vascular
endothelial cells in tumor tissues were largely derived from
nearby adipose tissues [26]. Thus, after circulating bone
marrow MSCs and peritumoral adipose tissue-derived
MSCs home to tumors, these two types of MSCs might
differentiate along different pathways.
The characteristics of T-MSCs
MSCs in tumor tissues are significantly affected by both
tumor cells and the chronically inflammatory tumor
microenvironment. In the following paragraphs, we will
discuss the differences between T-MSCs and N-MSCs
and the mechanisms that underlie these differences.
Many researchers have demonstrated that MSCs are
non-neoplastic and chromosomally normal in solid
tumors [48,49]. However, Lin et al. found that in certain
colon cancer patients, MSCs isolated from tumor tissues
exhibited the same chromosomal abnormalities that
were present in the colon cancer cells, while in the
remaining patients, the tumor cells exhibited chromosomal
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normal [50]. Moreover, p53 expression was observed to be
generally low or absent in colon cancer-derived MSCs [50].
Wang et al. found that in MSCs, long-term stimulation
with TNF-α, IFN-γ, and other factors could upregulate the
expression of various proto-oncogenes such as c-Fos and
c-Myc by activating the nuclear factor-kappa B (NF-kB)
signaling pathway. T-MSCs and N-MSCs have similar
phenotypes [48-52]; in particular, both types of MSCs
express high levels of CD29, CD44, CD90, and CD105, but
low levels of hematopoietic cell markers. The following
differences between T-MSCs and N-MSCs have been
observed: first, there are more MSCs in tumor tissues than
in normal tissues. For instance, this phenomenon is quite
evident in an examination of osteosarcoma tissues, as an
average of 1117 clones of MSCs can be obtained from 10
[5] osteosarcoma cells, but only 1.3 clones can be obtained
from 10 [5] normal bone marrow cells [49]. Examinations
of specimens from cancer patients have also demonstrated
that MSCs are more prevalent in tumor tissues than in
adjacent normal tissues [53]. Second, T-MSCs exhibit a
significantly greater proliferative capacity than N-MSCs. In
particular, T-MSCs isolated from ovarian [48], pulmonary
[46], stomach [54], and prostate [55] cancers, as well as
pediatric neuroblastoma, teratoma, Ewing sarcoma, and
rhabdomyosarcoma specimens [56], had shorter doublingtimes than N-MSCs. This phenomenon might occur
because T-MSCs express a number of proliferation-related
genes such as murine double minute 2, p21, and the zinc
finger transcriptional factor sal-like protein 4 that are not
expressed by N-MSCs [54]. Third, T-MSCs exhibit varying
differentiation capabilities. Only a small subset of the
MSCs isolated from pediatric neuroblastoma, teratoma,
Ewing sarcoma, and rhabdomyosarcoma specimens could
be induced to differentiate into adipocytes; however, these
T-MSCs responded to osteogenic induction similarly as
N-MSCs [56]. Fourth, T-MSCs exhibit stronger migratory
capabilities than N-MSCs. Gastric cancer-derived MSCs
were shown to possess particularly strong migratory
capabilities [54]. Finally, T-MSCs exhibit strong drug
resistance. MSCs derived from non-small-cell lung cancer
were more resistant to cisplatin when compared with
MSCs derived from normal lung tissue. Additional
functional differences between T-MSCs and N-MSCs
will be discussed further in the following section that
describes the effects of T-MSCs on tumors.
The effects of MSCs on tumors and the mechanisms that
underlie these effects
MSCs might exhibit extremely different functions in
distinct microenvironments because various signaling
pathways can be activated in these cells. As a result,
highly controversial results have been reported in prior
studies that addressed the role of MSCs in tumor
development. Therefore, it is very important to examine
how MSCs in different states affect tumors. Generally, the
MSCs used for clinical treatment are naïve MSCs that
were cultured in vitro from normal tissue sources. These
exogenous N-MSCs can carry exogenous genes, because
they home to tumor tissues and are therefore expected to
produce anti-tumor effects. Interactions between MSCs
and tumor cells in tumor tissues could become a new
cancer therapy target. In the following paragraphs, we will
discuss the effects of naïve MSCs, T-MSCs, and MSCs
that have been treated with various cytokines on tumors.
The effects of naïve (innate) MSCs on tumors
The earliest studies of MSCs and tumors focused on
the effects of naïve MSCs on tumors. Naïve MSCs
can inhibit tumor cell proliferation when co-cultured
with tumor cells in vitro. Ramasamy et al. reported
that N-MSCs could inhibit the proliferation of leukemia
cell lines and solid tumor cell lines in vitro. This inhibitory
effect of N-MSCs was dose-dependent, with stronger
levels of inhibition observed at higher proportions of
N-MSCs [57]. The underlying mechanism of this effect
could involve the N-MSC-mediated secretion of soluble
factors such as Dickkopf-related protein 1, which inhibits
Wnt signaling pathways in tumor cells; Wnt pathway
inhibition could, in turn, decrease c-Myc and Cyclin D2
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resulting in the suppression of cell cycle progression
[22,58-60]. Naïve MSCs also induce apoptosis in tumor
cells [23]. The mechanisms that underlie this effect could
involve the upregulation of caspase 3, an apoptosis-related
protease [58]. Additionally, naïve MSCs indirectly
suppress tumor growth by inhibiting angiogenesis.
N-MSCs can inhibit angiogenesis by inducing apoptosis in
vascular endothelial cells [61,62] or by directly inhibiting
vascular network formation [63]. However, opposing results
have also been reported. In an animal model of prostate
cancer, MSCs were shown to promote fibroblast growth
factor 2 (FGF2) secretion by PC3 cells. MSCs were also
observed to enhance the expression of endothelin-1 in
colon cancer cell lines [64], thereby promoting tumor
angiogenesis [30]. In a melanoma model, MSCs directly
differentiated into vascular endothelial cells [47]. Cancer
stem cells (CSCs) contribute to tumorigenesis, metastasis
and recurrence of tumors [65]. Naïve MSCs can also
enhance the proportion of CSCs in tumor cell populations.
Nishimura et al. observed that co-culturing gastric cancer
cell lines with MSCs increased the proportion of
CD133-positive gastric cancer cells [25,65]. Similarly,
Liu et al. found that co-culturing breast cancer cell lines
and MSCs increased the percentage of Aldefluor + cells
among the cancer cells. In animal models, MSCs were
found to form stem cell niches in breast cancer tissues,
with higher proportions of breast cancer stem cells present
in the vicinities of these niches than at other sites [29].
Furthermore, naïve MSCs promote tumor cell migration.
This effect might occur in response to various chemokines
that are expressed by MSCs, including CCL5 [66,67],
CXCR4 [68], intercellular adhesion molecules (ICAMs),
and vascular cell adhesion molecules (VCAMs) [69]. These
chemokines can function in a paracrine manner to not only
promote tumor invasion and tumor migration but
also facilitate EMT among tumor cells [70,71]. Finally,
in vivo, naïve MSCs can suppress immune responses,
thereby promoting tumor growth [72].
In summary, naïve MSCs have been reported to exert
bidirectional effects on tumor progression, and different
researchers have discrepancies on whether these MSCs
exert tumor-promoting or tumor-suppressing effects. These
discrepancies might reflect differences in experimental
conditions, as the results of each experiment reveal only
one aspect of the mechanisms by which N-MSCs affect
cancer cells. Additionally, the same researchers could
obtain completely opposite results from in vivo and
in vitro experiments. For instance, Ramasamy et al.
reported that N-MSCs inhibited tumor proliferation
in vitro, but that injecting MSCs could promote tumor
growth in nude mice. Ramasamy et al. explained these
findings by proposing that MSCs might form matrices to
provide nutritional support or form cancer stem cellniches [57]. In fact, after in vitro-cultured N-MSCs home
to tumors within animals, the N-MSCs will be clearly
affected by these tumors, and the states and functions of
the N-MSCs will be altered. Therefore, it is unsurprising
that in vivo and in vitro studies of N-MSCs would yield
differing results (Figure 2).
The effects of T-MSCs on tumors
T-MSCs exhibit stronger immunosuppressive activity
than N-MSCs Ren et al. found that, relative to bone
marrow-derived MSCs (BM-MSCs), MSCs isolated from
mouse lymphomas (L-MSCs) more strongly promoted
tumor growth. This effect was mainly due to the high
expression of CC motif chemokine receptor 2 (CCR2)
ligands in these cells, which could recruit immunosup-
pressive cells such as CD11b+ Ly6C+ monocytes, F4/80+
macrophages, and CD11b+Ly6G+ neutrophils to lymphoid
tissues. Monocyte/macrophage depletion or CCR2 gene
knockout eliminated the L-MSC-mediated tumor-promoting
effects [21]. Compared to MSCs isolated from normal breast
tissues, MSCs derived from breast cancer tissues express
higher levels of the immunosuppressive factors IL-4, IL-10,
and TGF-β1. Furthermore, co-culturing peripheral
blood mononuclear cells with breast cancer-derived
MSCs increased the proportion of CD4+CD25hiFoxp3+
regulatory T cells [73]. Cervical cancer-derived MSCs
significantly reduced the expression of human leukocyte
antigen (HLA) class I molecules (HLA-A*0201) on the
surface of cervical cancer line cells, thereby inhibiting the
cytotoxic effects of antigen-specific T cells on these
cervical cancer cells [74]. MSCs isolated from pediatric
sarcomas inhibited the cytotoxic effects of natural killer
(NK) cells by reducing the expression of the NK cell
receptors NKp44 and NKp46 [56].
T-MSCs play a role in promoting EMT Examinations
of tissue sections from pancreatic cancer patients revealed
that pancreatic cancer cells near T-MSCs exhibit reduced
E-cadherin expression and elevated vimentin expression
[75]. Additionally, CCL5 expression is upregulated in MSCs
from prostate cancer and breast cancer cell lines. The
upregulation of CCL5 expression is known to increase the
expression of various EMT-related genes such as zinc finger
E-box-binding homeobox 1, Snail, and CXCR4 [24,67].
T-MSCs promote tumor cell proliferation McLean et al.
reported that human ovarian cancer-derived MSCs
promoted tumor cell proliferation in mice, with an
accompanying increase in the proportion of Ki-67-positive
tumor cells; in contrast, as noted above, N-MSCs did not
significantly promote tumor proliferation [48].
T-MSCs increase the proportion of cancer stem cells
In vitro co-culture experiments have demonstrated that
Figure 2 Different effects of Naïve MSC (N-MSC) and (Tumor derived MSC (T- MSC) on tumors. Naïve MSCs are ‘educated ‘by the tumor
inflammatory microenvironment after homing to tumor tissues and transformation to T-MSCs exert different effects on tumor development.
Promote Inhibit Controversial.
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cancer stem cells in ovarian cancer cell population. The
mechanism that underlies this effect might be related to
the greater expression levels of the bone morphogenetic
proteins (BMPs) BMP2, BMP4, and BMP6 in ovarian
cancer-derived MSCs, relative to N-MSCs. In particular,
in vitro experiments indicated that BMP2 could simulate
the effects of T-MSCs on cancer stem cells. Inhibition of
the BMP signaling pathway abolished the MSC-mediated
promotion of tumor growth [48]. Co-cultures of prostate
cancer cells and BM-MSCs significantly increased the se-
cretion of CCL5 by BM-MSCs. In prostate cancer cell lines,
CCL5 enhanced the proportion of stem cells (CD133+ cells)
in cell populations and promoted sphere formation [24].
To summarize the above-described findings, in contrast
to naïve MSCs, T-MSCs indisputably promote tumor
progression (Figure 2).
TLR4-mediated MSC activation
Tumors, the inflammatory tumor microenvironment, and
T-MSCs typically form a mutually reinforcing vicious
cycle. However, the activation of various surface receptors
on MSCs could induce MSCs to adopt tumor-inhibiting
phenotypes. Waterman et al. found that after activating
Toll-like receptor 4 (TLR4) on MSCs with lipopolysac-
charide (LPS) stimulation, MSCs secreted large quantities
of various proinflammatory mediators, including IL-17,
IL-3, monokine induced by gamma-interferon (MIG),
macrophage inflammatory protein-1 beta (MIP1b),
and granulocyte-macrophage colony-stimulating factor
(GM-CSF). In vitro experiments have indicated that
MSCTLR4, a proinflammatory MSC phenotype induced
by TLR4 priming, supports T cell activation. MSCTLR4
promoted inflammation in a mouse model of inflammatory
lung injury. In an ovarian cancer model, MSCTLR4 actedto recruit F4/80+ leukocytes (likely macrophages) and
monocytes, whereas naïve MSCs recruited tumor-
associated granulocytes [76]. Therefore, in a mouse model
of ovarian cancer, MSCTLR4 did not promote tumor growth
and metastasis. These results indicate that MSCs could be
converted to a phenotype that is detrimental to tumor
progression. Further studies are warranted to determine
the effects of MSCTLR4 on EMT, stem cell proportions,
and angiogenesis in the context of tumors.
The mechanisms that produce differences between
N-MSCs and T-MSCs
In the above discussions, we have described the differences
between the effects of naïve MSCs and T-MSCs on tumors.
These differences are mainly caused by the cytokines
present in the inflammatory tumor microenvironment.
MSCs express numerous cytokine receptors and therefore
have the capacity to respond to various types of signals.
Changes in the biological functions of MSCs can
occur through ligand-receptor binding and the resulting
activation of the corresponding signal pathways.
Inflammatory cytokine stimulation can enhance the
immunosuppressive effects of MSCs
IFN-γ or TNF-α can enhance the immunosuppressive
effects of MSCs [77,78]. Ren et al. found that, similarly to
MSCs isolated from lymphomas, TNF-α-treated MSCs
expressed high levels of CCR2 ligands and could recruit
immunosuppressive cells [21]. In a mouse model of
melanoma, the co-transplantation of B16 cells with
IFN-γ and TNF-α-pretreated MSCs promoted tumor
growth. IFN- γ and TNF-α pretreatment causes MSCs
to secrete large quantities of inducible nitric oxide
synthase (iNOS). This disrupted iNOS expression reverses
the observed tumor-promoting effects of MSCs [79]. IL-1α
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MSCs. The co-injection of prostate cancer cell lines with
IL-1α-treated MSCs promotes tumor growth in mice. This
tumor growth-promoting effect of IL-1α-pretreated MSCs
can be blocked by siRNAs against TGF-β [80].
Inflammatory cytokines can enhance the tumor
metastasis-promoting effects of MSCs
Inflammatory cytokine stimulation enhances the tumor
metastasis-promoting effects of MSCs. There are several
potential mechanisms that might underlie this effect; for
example, inflammatory cytokines could enhance the ability
of MSCs to promote EMT or upregulate the expression of
chemokines or ligands by MSCs. MSC pretreatment with
IFN-γ and TNF-α upregulates TGF-β expression in the
treated MSCs, and TGF-β can promote EMT. Experiments
both in vitro and in animal models of liver cancer have
demonstrated that, compared with conditioned medium
from untreated and single-factor treatment groups,
conditioned medium from MSCs pretreated with IFN-γ
and TNF-α significantly promoted invasion by liver cancer
cells. In mouse models of liver cancer, conditioned medium
from pretreated MSCs significantly increased metastasis
[81]. MSCs directly pretreated with TGF-β could promote
EMT in pancreatic cancer cell lines [34]. TNF-α promotes
the expression of the CXCR3 ligands CXCL9, CXCL10
and CXCL11 in MSCs and thereby promotes migration in
breast cancer cell lines [82].
Inflammatory cytokines promote the secretion of
angiogenic factors by MSCs
Pretreatment with IFN-γ and TNF-α induces VEGF
expression in MSCs via the HIF-1 α signaling pathway,
thereby enhancing the ability of MSCs to promote tumor
angiogenesis. Inhibiting HIF-1α expression in MSCs
abolishes the ability of MSCs to promote colon cancer
growth in an inflammatory tumor microenvironment [75].
Treatment of MSCs with inflammatory cytokines promotes
the expression of cancer stem cell-related genes
TGF-β-pretreated MSCs can increase the expression of
various stemness-related proteins such as CD133, Nanog,
and octamer-binding transcription factor 4 in in pancreatic
cancer cells and enhance the sphere-forming capacity of
these cancer cells [77].
The effects of tumor-secreted exosomes on MSCs
Exosomes are small vesicles (typical diameter, 30–100 nm)
that are secreted by a variety of living cells. The exosomal
lumen mainly contains cytoplasm; thus, exosomes can
transport various molecules between cells. Exosomes
derived from breast and ovarian cancer cells can cause
adipose-derived MSCs to adopt TAF phenotypes, with
upregulated α-SMA expression. Additionally, exosomescan promote expression of the tumor-associated factors
such as SDF-1, VEGF, CCL5, and TGF-β in MSCs [78,83].
Conclusion
Tumors cause inflammation, and inflammatory tumor
microenvironments recruit MSCs from the circulation and
adjacent tissues to tumor tissues, thereby educating these
MSCs to adopt tumor growth-promoting phenotypes.
MSCs in tumor tissues recruit additional immunosuppres-
sive cells, resulting in the formation of an immunosuppres-
sive microenvironment in the tumor vicinity. MSCs can
also enhance the proportions of cancer stem cells in
tumors, promote EMT, and stimulate tumor angiogenesis.
These effects contribute to tumor growth, progression, and
metastasis, leading to the formation of a vicious cycle.
However, given the plasticity of MSCs, alterations to the
activated signaling pathways could potentially convert these
MSCs to phenotypes that would inhibit tumor growth and
development. Studies of not only the interactions among
tumors, MSCs, and the inflammatory tumor microenviron-
ment but also of methods to interrupt these interactions
will likely provide new cancer therapy targets.
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